Cleveland BioLabs Company Profile (NASDAQ:CBLI)

About Cleveland BioLabs

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company's programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CBLI
CUSIP:

Key Metrics:

Previous Close: $1.61
50 Day Moving Average: $1.9809
200 Day Moving Average: $2.3761
52-Week Range: $1.55 - $4.89
Trailing P/E Ratio: N/A
P/E Growth: 0.0000
Market Cap: $18.67M
Outstanding Shares: 10,987,000
Beta: 0.9

Profitability:

Net Margins: -27.51%
Return on Equity: -7.42%
Return on Assets: -5.13%

Debt:

Current Ratio: 3.66%
Quick Ratio: 3.66%

Additional Links:

Companies Related to Cleveland BioLabs:

Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/15/2016	Q2		($0.17)			View	N/A
5/16/2016	Q116		($0.06)			View	N/A
2/22/2016	Q4		($0.03)			View	N/A
11/5/2015	Q315		($0.31)	$415.00 million		View	N/A
8/12/2015	Q215		($1.12)	$562.10 million	$329.90 million	View	Listen
5/6/2015	Q115		($1.14)	$1.33 million		View	N/A
2/24/2015	Q114		($1.02)	$3.87 million	$1.39 million	View	N/A
8/7/2014	Q2		($0.09)			View	N/A
5/8/2014		($0.05)	($0.03)			View	N/A
3/11/2014	Q413	($0.12)	($0.01)	$1.74 million	$3.87 million	View	N/A
11/6/2013	Q313	($0.14)	($0.09)	$1.61 million	$1.60 million	View	N/A
8/13/2013	Q2 2013	($0.16)	($0.07)	$1.48 million	$1.60 million	View	N/A
5/9/2013	Q1 2013	($0.17)	($0.22)	$1.73 million	$1.37 million	View	N/A
11/8/2012	Q312	($0.02)	($0.30)	$23.87 million		View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cleveland BioLabs (NASDAQ:CBLI)

Insider Ownership Percentage: 3.21%
Institutional Ownership Percentage: 3.72%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/25/2015	Randy S Saluck	Director	Buy	1,891	$3.42	$6,467.22
5/21/2013	Paul E Dicorleto	Director	Buy	6,210	$1.61	$9,998.10
5/17/2013	Randy S Saluck	Director	Buy	3,500	$1.60	$5,600.00
3/15/2013	James Antal	Director	Buy	3,700	$1.56	$5,772.00
9/21/2012	James Antal	Director	Buy	2,316	$2.60	$6,021.60

(Data available from 1/1/2013 forward)

Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)

Date	Headline
	ETF’s with exposure to Cleveland BioLabs, Inc. : September 12, 2016 (NASDAQ:CBLI) www.capitalcube.com - September 12 at 3:57 PM
	ETF’s with exposure to Cleveland BioLabs, Inc. : August 30, 2016 (NASDAQ:CBLI) www.capitalcube.com - August 30 at 11:57 AM
	ETF’s with exposure to Cleveland BioLabs, Inc. : August 19, 2016 (NASDAQ:CBLI) www.capitalcube.com - August 19 at 4:45 PM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 (NASDAQ:CBLI) www.capitalcube.com - August 18 at 12:31 PM
	Cleveland Biolabs Inc. Reports Second Quarter 2016 Financial Results And Development Progress (NASDAQ:CBLI) www.biospace.com - August 17 at 12:19 PM
	Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress (NASDAQ:CBLI) www.publicnow.com - August 15 at 11:20 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CBLI) biz.yahoo.com - July 22 at 4:22 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta (NASDAQ:CBLI) biz.yahoo.com - July 21 at 6:05 AM
	ETF’s with exposure to Cleveland BioLabs, Inc. : July 19, 2016 (NASDAQ:CBLI) www.capitalcube.com - July 19 at 12:08 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand (NASDAQ:CBLI) biz.yahoo.com - July 12 at 4:25 PM
	Cleveland BioLabs Announces Board Resignations (NASDAQ:CBLI) www.publicnow.com - July 12 at 9:13 AM
	Services Sector Daily Watch: Winners & Losers (NASDAQ:CBLI) www.fxpips.com - June 22 at 8:51 AM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:CBLI) www.capitalcube.com - May 17 at 12:26 PM
	Friday Morning’s Top Movers – UNIS, HTGM, ORMP, NVDA, CETX, CBLI, RUN (NASDAQ:CBLI) www.fxpips.com - May 16 at 2:01 PM
	Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress (NASDAQ:CBLI) www.publicnow.com - May 16 at 8:02 AM
	22nd Century to begin cannabis research at new medical campus labs (NASDAQ:CBLI) www.bizjournals.com - May 12 at 2:40 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit (NASDAQ:CBLI) biz.yahoo.com - May 6 at 5:55 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CBLI) biz.yahoo.com - April 15 at 3:05 PM
	Cleveland BioLabs Announces Webcast of Annual Meeting (NASDAQ:CBLI) www.publicnow.com - April 4 at 7:37 AM
	GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag (NASDAQ:CBLI) www.rttnews.com - March 17 at 2:04 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events (NASDAQ:CBLI) biz.yahoo.com - March 16 at 2:50 PM
	Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure (NASDAQ:CBLI) finance.yahoo.com - March 16 at 2:00 PM
	Hottest Services Stocks Now – CAI NEWT INST MOBL (NASDAQ:CBLI) investorplace.com - March 8 at 11:42 AM
	CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report (NASDAQ:CBLI) biz.yahoo.com - February 23 at 5:04 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:CBLI) biz.yahoo.com - February 22 at 10:35 AM
	Cleveland BioLabs Reports 2015 Financial Results and Development Progress (NASDAQ:CBLI) finance.yahoo.com - February 22 at 7:30 AM
	Cleveland BioLabs, Inc. (CBLI) (NASDAQ:CBLI) biz.yahoo.com - February 18 at 6:31 PM
	Hottest Services Stocks Now – ADUS SREV EBIX CBLI (NASDAQ:CBLI) investorplace.com - February 9 at 10:47 AM
	Cleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis (NASDAQ:CBLI) www.streetinsider.com - February 9 at 10:47 AM
	Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute (NASDAQ:CBLI) finance.yahoo.com - February 9 at 7:30 AM
	Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation (NASDAQ:CBLI) finance.yahoo.com - February 2 at 8:00 AM
	Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation (NASDAQ:CBLI) www.publicnow.com - January 26 at 7:49 AM
	Cleveland BioLabs Gets Orphan Status for Entolimod in EU (NASDAQ:CBLI) finance.yahoo.com - January 22 at 3:25 PM
	Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure (NASDAQ:CBLI) www.noodls.com - January 21 at 7:45 AM
	7:30 am Cleveland Biolabs announces that entolimod has been granted orphan drug status by the EMA for treatment of acute radiation syndrome (NASDAQ:CBLI) finance.yahoo.com - January 21 at 7:30 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defin (NASDAQ:CBLI) biz.yahoo.com - December 24 at 1:04 PM
	Cleveland BioLabs and Rusnano Make Additional Investments in Panacela (NASDAQ:CBLI) www.noodls.com - December 22 at 7:40 AM
	Cleveland BioLabs, Inc. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:CBLI) www.capitalcube.com - December 16 at 1:16 PM
	Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute (NASDAQ:CBLI) finance.yahoo.com - December 14 at 7:30 AM
	CLEVELAND BIOLABS INC Financials (NASDAQ:CBLI) finance.yahoo.com - December 8 at 1:17 PM
	Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod (NASDAQ:CBLI) www.noodls.com - November 30 at 8:00 AM
	CLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:CBLI) biz.yahoo.com - November 9 at 4:17 PM
	Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress (NASDAQ:CBLI) www.noodls.com - November 5 at 7:40 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:CBLI) biz.yahoo.com - November 5 at 7:31 AM
	Q3 2015 Cleveland Biolabs Inc Earnings Release - Time Not Supplied (NASDAQ:CBLI) biz.yahoo.com - November 5 at 7:07 AM
	Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5 (NASDAQ:CBLI) www.noodls.com - October 27 at 8:15 AM